ArticleFrontiers in aging2026
Development and validation of a machine learning-based risk prediction model for sarcopenia in community hospital patients: a retrospective cohort study.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenia, a progressive age-related loss of skeletal muscle mass and strength, represents a growing public health challenge amid global population aging. Early detection remains difficult with conventional diagnostic approaches. Methods: This study aimed to develop and validate reliable machine learning (ML) models to identify key risk factors for sarcopenia in community hospital settings. Using retrospective data from 1,650 patients at a community health center, we collected comprehensive demographic, clinical, and lifestyle variables. Twelve ML models-including Random Forest, Support Vector Machine, XGBoost, and Logistic Regression-were constructed and evaluated using 5-fold cross validation. Results: The CatBoost, LightGBM, and Gradient Boosting Decision Tree models demonstrated superior predictive performance, with area under the receiver operating characteristic curve (AUROC) values of 0.999, 0.996, and 0.995, respectively. SHapley Additive exPlanations (SHAP) analysis revealed that SARC_Cal_score, body mass index (BMI), and age belong to the most influential predictors, while a greater chronic disease burden was positively associated with sarcopenia risk. Conclusion: In conclusion, ML models show substantial potential for clinical application in identifying sarcopenia risk, thereby supporting early intervention strategies. This approach enhances detection capabilities and provides a practical tool for individualized treatment planning in community-based elderly care. Future research should integrate additional biomarkers and environmental factors to further improve model accuracy and facilitate integration into clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.